Medication info
VR Tablet 20/160 Milligrams

VR Tablet 20/160 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
Brown oval film-coated tablets
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 202001382 · Approved 2020.02.27

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; reduction of atherosclerotic and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and it may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose is then increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. 4. Patients with renal impairment: No dosage adjustment is required when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy have not been established in children and adolescents under 18 years of age. The safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; reduction of atherosclerotic and cardiovascular risk

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • Dysbetalipoproteinemia
View approved original text

This medication contains Valsartan, used to reduce the risk of death after myocardial infarction, as well as Rosuvastatin, used to reduce several forms of hypercholesterolemia and cardiovascular disease risk. Valsartan is primarily used to reduce the risk of death in patients with essential hypertension, heart failure, or impaired left ventricular function after myocardial infarction. Rosuvastatin helps lower cholesterol levels in patients with hypercholesterolemia, inhibits the progression of atherosclerosis, and reduces the risk of cardiovascular disease, stroke, and myocardial infarction. These two components must be administered together and are effective in improving cardiovascular health and reducing risk.

How to take

Adult dose

This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and it may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose is then increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. 4. Patients with renal impairment: No dosage adjustment is required when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy have not been established in children and adolescents under 18 years of age. The safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Individuals with allergies to this medication, pregnant or potentially pregnant women, and nursing mothers should not take this medication. Patients with severe liver or kidney dysfunction, specific genetic diseases or myopathy should also avoid this medication. Elderly patients, patients with hyperkalemia, and patients with liver impairment should exercise caution when taking this medication and have regular liver function and kidney function tests. This medication can cause muscle pain, muscle weakness, and, rarely, severe muscle damage known as rhabdomyolysis, so consult a physician immediately if you experience muscle pain or weakness. Additionally, since this medication can affect liver function, it should be discontinued and a physician consulted if symptoms of hepatitis or jaundice occur. During treatment with this medication, there may be drug interactions with other medications, so inform healthcare providers about any other medications being taken. Particularly, caution should be exercised when taken with potassium-sparing diuretics or potassium supplements, as this can dangerously elevate potassium levels in the blood. Symptoms such as dizziness or drowsiness may occur while driving or operating machinery, so caution is advised. This medication has not been established for safety or efficacy in children and adolescents, so it is best to avoid its use. In case of overdose, there is a risk of decreased consciousness and low blood pressure, requiring immediate medical attention.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver amino transferase, increased serum creatinine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fractures, spinal fractures, fractures, skin neoplasm, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, herniated disc, hemoptysis, sputum disease, bronchitis, sensory disturbances, hoarseness, gastroesophageal reflux, diverticulitis, stomatitis, gastritis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsened hypertension, neck/shoulder pain, toe fractures, osteomyelitis, skin infection, unspecified skin inflammation, localized skin reaction, palpitations, worsened angina, auditory disturbances, overactive bladder, increased serum creatinine, vitreous detachment, reproductive dysfunction, prostatic hypertrophy, laceration, anemia, tinnitus, hypertonia, decreased motor function, stupor, rash, myalgia, headache, dizziness, constipation, abdominal pain, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia and systemic symptom-associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, cough, dyspnea, diarrhea, fatal and non-fatal liver failure, sexual dysfunction, gynecomastia, memory decline, forgetfulness, amnesia, memory impairment, confusion, hypotension, orthostatic dizziness, orthostatic hypotension, renal function impairment, hyperkalemia, angioedema, erythema, pruritus, serum sickness, vasculitis, syncope, epistaxis, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduced red blood cell volume, decreased hemoglobin, edema, weakness, insomnia, erythema, decreased libido, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light; therefore, it should be stored in a container that does not allow light to penetrate. Also, to maintain the drug's effectiveness, it is important to store it at room temperature, between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Brown oval film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.